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Abstract
During RNA virus replication, there is the potential to incorporate mutations that affect virulence or pathogenesis. For live-
attenuated vaccines, this has implications for stability, as replication may result in mutations that either restore the wild-
type phenotype via reversion or compensate for the attenuating mutations by increasing virulence (pseudoreversion).
Recent studies have demonstrated that altering the mutation rate of an RNA virus is an effective attenuation tool. To vali-
date the safety of low-fidelity mutations to increase vaccine attenuation, several mutations in the RNA-dependent RNA-po-
lymerase (RdRp) were tested in the live-attenuated Venezuelan equine encephalitis virus vaccine strain, TC-83. Next gener-
ation sequencing after passage in the presence of mutagens revealed a mutant containing three mutations in the RdRp, TC-
83 3x, to have decreased replication fidelity, while a second mutant, TC-83 4x displayed no change in fidelity, but shared
many phenotypic characteristics with TC-83 3x. Both mutants exhibited increased, albeit inconsistent attenuation in an in-
fant mouse model, as well as increased immunogenicity and complete protection against lethal challenge of an adult mu-
rine model compared with the parent TC-83. During serial passaging in a highly permissive model, the mutants increased
in virulence but remained less virulent than the parent TC-83. These results suggest that the incorporation of low-fidelity
mutations into the RdRp of live-attenuated vaccines for RNA viruses can confer increased immunogenicity whilst showing
some evidence of increased attenuation. However, while in theory such constructs may result in more effective vaccines,
the instability of the vaccine phenotype decreases the likelihood of this being an effective vaccine strategy.
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1. Introduction
Due to the error-prone nature of the RNA-dependent RNA-
polymerase (RdRp), RNA virus replication is characterized by a
high mutation rate that results in increased genetic diversity of
progeny viruses (Domingo et al. 2005). This diversity can be uti-
lized by the virus to evade and escape the immune system, as
well as to adapt to new hosts. Maintaining the correct amount
of virus diversity of 1 mutation per genome (Nebot et al. 2010)
is of utmost importance to RNA virus survival within the host
and during transmission. This is especially true for arboviruses
(arthropod borne viruses), which utilize two distinct hosts to
complete their transmission cycle. If the mutation rate of an
RNA virus is too high, more unfit progeny will be produced due
to the increased number of mutations, most of which are dele-
terious by chance. This results in a substantial decrease in via-
ble genomes, and possible extinction of the viral population due
to error catastrophe (Manrubia et al. 2010). Conversely, if the
mutation rate is too low, little variation is produced, and the vi-
rus population becomes clonal and less able to adapt to diverse
environments. Both scenarios reduce the overall fitness of the
virus and can lead to extinction (Escarmı´s et al. 2008). This pre-
dicted lack of fitness with high- or low-fidelity replication has
been demonstrated experimentally with a number of viruses,
including poliovirus (PV) (Pfeiffer and Kirkegaard 2003; Vignuzzi
et al. 2006), chikungunya virus (CHIKV) (Coffey et al. 2011;
Rozen-Gagnon et al. 2014), West Nile virus (Van Slyke et al.
2015), St Louis encephalitis virus (Griesemer et al. 2017), human
enterovirus 71 (Sadeghipour and McMinn 2013; Sadeghipour
et al. 2013; Meng and Kwang 2014), foot and mouth disease virus
(Arias et al. 2008; Zeng et al. 2013, 2014; Xie et al. 2014), SARS
CoV (Eckerle et al. 2010; Graham et al. 2012; Graepel et al. 2017),
influenza virus (Cheung et al. 2014; Pauly et al. 2017), Norovirus
(Arias et al. 2016) and Coxsackie B virus (Gna¨dig et al. 2012;
Levi et al. 2010; McDonald et al. 2016). These viruses were all
subjected to treatment with nucleoside analogs such as
Ribavirin or 5’Fluorouracil, which increases the mutation rate
and can lead to virus extinction, or by the insertion of muta-
tions found to change fidelity in other viruses. Virus popula-
tions circumvent extinction by developing resistance to the
nucleoside analog, sometimes by developing mutations in the
RdRp that either increase (high fidelity) or decrease (low fidel-
ity/hypermutator) RdRp fidelity (i.e. the RdRp error-rate). When
compared with unpassaged, wild-type (wt) viruses, fidelity mu-
tants have similar growth kinetics in vitro, but are attenuated
in vivo due to the alteration of diversity produced during replica-
tion, which hampers the ability of the virus to overcome
bottlenecks in the host (Pfeiffer and Kirkegaard 2005; Vignuzzi
et al. 2006).
The alphavirus genus, family Togaviridae, contains a number
of important arboviruses that are distributed worldwide.
Alphaviruses are classified as either Old World or New World vi-
ruses depending on their distribution. Venezuelan equine en-
cephalitis virus (VEEV) is a New World encephalitic alphavirus
that circulates continuously in an enzootic cycle in the forests
and swamps of northern South America, Central America and
Mexico, typically between rodents and mosquitoes. Spillover
from this cycle is believed to cause tens of thousands of
dead-end human infections annually (Aguilar et al. 2011).
Periodically, the virus emerges to cause epizootic cycles in
equids, which can also spill over into humans, sometimes re-
sulting in hundreds of thousands of infections (Sudia et al. 1975;
Wang et al. 2001; Brault et al. 2002; Weaver et al. 2004;
Anishchenko et al. 2006). Prior to the 1960s, equine epizootics
involving high fatality rates were frequently recorded in VEEV-
endemic areas. Since horses remain important components of
the local agricultural economies within these regions, VEEV has
had a major impact on the economic output of at-risk areas
(Walton and Grayson 1988). Recent outbreaks in both Venezuela
and Mexico demonstrate the ability of VEEV to re-emerge peri-
odically from its enzootic niche (Rico-Hesse et al. 1995; Weaver
et al. 1996; Oberste et al. 1998), and some earlier outbreaks
spread as far north as Texas (Lord 1974; Sudia et al. 1975).
Independent of these natural cycles of infection, there is great
concern for the use of VEEV as a biological weapon due to its
high infectivity via the aerosol route. To address this threat,
multiple vaccines have been developed to protect against VEEV
infection.
The first human vaccine described for VEE, TC-83, was pro-
duced following 83 serial passages of the Trinidad donkey VEEV
strain (subtype IAB) in guinea pig heart cells (Berge et al. 1961).
Sequencing of TC-83 revealed eleven nucleotide changes, but at-
tenuation was attributed to only 2 of these mutations; one in the
5’ UTR (untranslated region) and one in the E2 glycoprotein gene
(Kinney et al. 1989, 1993). The reliance of TC-83 on only two point
mutations for its attenuation increases the potential for reversion
during vaccination, as well as instability during manufacturing.
This concern has been supported by passaging in infant mice,
where TC-83 reverted in a little as three intracranial passages
(Mckinney et al. 1963). The retention of mosquito infectivity adds
another safety concern for transmission from vaccinees to hu-
mans or equids, and the isolation of TC-83 from wild-caught
mosquitoes in 1971 during an equine vaccination campaign un-
derscores this risk (Pedersen et al. 1972). Due to these concerns,
as well its incomplete immunogenicity (Mckinney et al. 1963;
Alevizatos et al. 1967; Engler et al. 1992), TC-83 is only approved
for equids, but it maintains investigational new drug status for
at-risk military and laboratory personnel.
The presence of a high mutation rate is thought to be one
reason for the persistence of RNA viruses in the environment.
However, high mutation rates also have implications for live-
attenuated vaccines (LAV’s) such as TC-83, which typically
generate long-lived immunity and are cost-effective. LAV repli-
cation has the potential to restore a virulent, wt phenotype via
one or more reversions or pseudoreversions. Such events can
lead to safety concerns and possible adverse events following
immunization (Roukens and Visser 2008). However, further in-
creasing the natural mutation rate is also hypothesized to de-
crease the ability of the virus to successfully revert or
pseudorevert through Muller’s ratchet (Muller 1964; Chao 1990),
by the accumulation of deleterious mutations in asexual popu-
lations (e.g. viruses) during replication in the absence of effi-
cient recombination. Additionally, deleterious mutations can
also impair the ability of fitter viruses to replicate and increase
in the population (Duarte et al. 1992; Escarmıs et al. 1999;
Escarmı´s et al. 2008). Thus, the RNA virus error rate is finely
tuned to allow for optimal virus population health while also al-
lowing for the production of mutations, which are key for adap-
tation to new hosts and environments.
The present study was designed to determine whether mu-
tations in the TC-83 RdRp that alter virus fidelity, i.e. increasing
the mutational spectrum, can attenuate the virus further,
without sacrificing vaccine stability or immunogenicity. We
discovered 3 RdRp mutations that conferred a hypermutator
phenotype. Additionally, a variant with four mutations in the
RdRp was found to have no evidence of a change in diversity af-
ter one cell culture passage, but shared many characteristics in
common with the low-fidelity mutant. These mutants both
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resulted in increased phenotypic stability compared with wt vi-
rus, as well as an increase in immunogenicity and protection in
a mouse model.
2. Results
2.1 RdRp mutant identification
To identify mutations in the RdRp gene associated with changes
in fidelity, TC-83 rescued from an infectious clone was used to
initiate serial Vero cell passages in duplicate in the presence of
Ribavirin, 5’Flurouracil (5FU), or Azacytidine (Aza). Viruses were
titered using plaque assays following each passage, and diluted
to an MOI of 1 plaque forming unit (PFU)/cell for each subse-
quent passage. Following Passages 19 and 23, the RdRp gene
(nsP4) was sequenced. Three mutations were identified in both
5FU passages, and all were located in the 5’ end of the RdRp
gene: a G5726C mutation resulting in the amino acid change
G14R, an A5794G mutation resulting in the amino acid change
E37G, and a G5970A mutation resulting in the amino acid
change A96T (amino acid numbers refer to nsP4 residues).
2.2 Cloning of TC-83 mutants
The three mutations identified following the 5FU passages were
cloned into the TC-83 backbone in conjunction with a high fidel-
ity mutation that was previously identified in a related alphavi-
rus, CHIKV (C483Y, which corresponds to position 488 in TC-83)
(Coffey et al. 2011). Six mutants were created (Fig. 1A), four of
which were individual mutants, and two with multiple muta-
tions: a 3x mutant including G14R, E37G and A96T and a 4x mu-
tant including G14R, E37G, A96T and C488Y. All clones were
rescued by electroporation into baby hamster kidney (BHK)
cells, and were titered using standard plaque assays on Vero
cells (Beaty et al. 1995). All rescued mutants were viable, pro-
ducing between 7 and 9 log10 PFU/ml following electroporation
(data not shown).
2.3 Replication kinetics
As the mutants included amino acid changes in the RdRp of
VEEV TC-83, the viruses were subjected to standard replication
curves on Vero cells (Fig. 1B). No mutants showed significant
differences from TC-83 by repeated measures ANOVA. Since
Vero cells are interferon-deficient, we used human embryonic
kidney (HEK)-293 cells to examine the effects of interferon on
the replication of fidelity-altered viruses. TC-83, the 3x mutant
and the 4x mutant were subjected to one-step replication
curves (Fig. 1C). As in Vero cells, no significant differences were
observed between the viruses and their TC-83 parent.
2.4 Resistance to nucleoside analog treatment
To confirm the ability of the RdRp mutations to confer resis-
tance to 5FU treatment (Fig. 1D), Vero cells were treated with 0,
10, 25, 50, 100, 200 or 300 mg/ml of 5FU and infected with parent
TC-83 or an RdRp mutant using an MOI of 0.01. Repeated mea-
sures ANOVA found no significant differences between the
RdRp mutants and parent TC-83 when Vero cells were treated
with 0–25 mg/ml 5FU. However, treatment with higher 5FU con-
centrations caused titers for all single RdRp mutants to drop
compared with parent TC-83, demonstrating increased sensitiv-
ity to the treatment. Of note, E37G was significantly different
from parent TC-83 for all of the high 5FU concentrations
(p < 0.01 for the 50 mg/ml treatment, p < 0.0001 for the
100-300ug/ml treatments). A96T was slightly more resistant,
with titers significantly reduced compared with parent TC-83
when cells were treated with 100–300 mg/ml (p < 0.0001). G14R
and C488Y were the most resistant to 5FU treatment of the sin-
gle mutants. Titers were only significantly reduced compared
with parent TC-83 for the 200–300 mg/ml treatments (p < 0.5 for
G14R 300 mg/ml, p < 0.0001 for all others). Due to the increased
sensitivity of these mutants to 5FU, it was unlikely that these
single mutations caused the resistance observed during the ini-
tial fidelity mutant selection.
Unlike the single RdRp mutants, TC-83 3x and 4x generally
had similar or slightly higher virus titers compared with parent
TC-83, suggesting increased resistance to 5FU treatment. TC-83
4x titers were significantly higher during the 50 and 100 mg/mL
treatments (p < 0.01 and 0.0001, respectively), and TC-83 3x ti-
ters were also significantly higher during the 100ug/mL treat-
ment (p < 0.05).
To determine if the RdRp mutants reacted similarly upon ex-
posure to another nucleoside analog, TC-83 and the RdRp mu-
tants were exposed to various concentrations of Ribavirin
(Fig. 1E). No significant difference was observed, except for the
G14R mutant, which displayed increased sensitivity (p < 0.01 for
100 and 300 mM, p < 0.001 for 400 mM).
2.5 Virulence in infant mice
To assess virulence, individual TC-83 mutants were injected in-
tracranially into 6-day-old CD-1 mice at a titer of ca. 5 log10 PFU
(backtiters ranged from 1.9  104–2.4  105 per dose). Mice were
weighed daily and the time of death was recorded (Fig. 2A). The
TC-83 3x mutant was significantly more virulent than the par-
ent virus, with all animals succumbing by Day 2 compared with
TC-83, where mice began succumbing at Day 3 (p  0.05,
Kaplan-Meier test). The mean time to death for parent TC-83
and all mutants except TC-83 3x was 5.36–5.54 days after infec-
tion, whereas TC-83 3x showed a mean time to death of 3.91
days.
Fidelity mutants have an impaired ability to overcome host
bottlenecks, which results in reduced mortality and titer in
certain organs (Pfeiffer and Kirkegaard 2005; Vignuzzi et al.
2006, 2008; Graham et al. 2012;). To test this, individual mu-
tants were injected subcutaneously into 6-day-old CD-1 mice
to measure their ability to cause mortality (backtiters ranged
from 6.2  103 to 1.35  105 per dose). TC-83 3x and TC-83 4x
exhibited significantly reduced mortality as reflected in sur-
vival (Kaplan-Meier test, p  0.05) when injected subcutane-
ously, compared with the original TC-83, and compared with
intracranial injection in 6-day-old CD-1 mice (Fig. 2B). The re-
maining mutants caused similar mortality to original TC-83,
suggesting no change in their ability to traverse bottlenecks to
cause fatal disease.
2.6 Illumina sequencing for virus population variants
To examine how different hosts in the arbovirus transmission
cycle alter virus diversity, TC-83, as well as the 3x and 4x mu-
tants, were passaged once using primate (Vero or HEK-293) or
mosquito (C7/10 or U4.4) cells and compared with the parental
virus (Fig. 3). TC-83 3x and 4x were the only RdRp mutants cho-
sen for this analysis, because they were most likely to have al-
tered fidelity as measured by a preliminary Illumina sequencing
analysis measuring the diversity of one replicate of each RdRp
mutant (data not shown), as well as the phenotypic tests exam-
ined in Figs 1 and 2. Illumina sequencing showed that the 3x
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mutant produced a significantly higher amount of genetic di-
versity than parental TC-83, independent of the cell type used
(Fig. 3A). This, along with the previously discussed results, indi-
cated that the 3x mutant is a low-fidelity variant. Interestingly,
the 4x mutant did not demonstrate a significant increase or de-
crease in diversity compared with TC-83. Cell type had no sig-
nificant effect on virus diversity, at least not after one passage.
When the number of nucleotide positions containing diversity
was examined (Fig. 3B), the 3x mutant trended towards produc-
ing an increased number of positions with diversity, while the
4x mutant, again, looked much like the parent TC-83.
Lastly, because TC-83 3x and 4x only appear to be resistant
to one nucleoside analog (Fig. 1D and E), it was important to de-
termine if this resistance is due to an alteration in the types of
mutations being made by these RdRp mutants (Fig. 3C). Indeed,
both TC-83 3x and 4x produced much fewer U-C mutations.
Because 5FU is a uracil analog and Ribavirin is not, this explains
the difference in nucleoside analog susceptibility.
When examining peaks of diversity across the virus genome,
some hotspots were conserved between the parent virus and
RdRp mutants (Fig. 4, Supplementary Figs S1–S4). These in-
cluded nsP2 C2627A (Asp-Glu) and A2634Del (Met-stop),
E2 T9561G (minus strand, Val-Gly), 6k C9978A (Ala-Asp) and
E1 C11009A (minus strand, Arg-Ser). The parent TC-83 and, to a
reduced extent, TC-83 4x both produced diversity hotspots in
E1, but generally in different positions. In TC-83 4x, these con-
sisted of C10032T (Ala-Val), T10356C (Val-Leu) and C11009A
(Ala, minus strand, synonymous), while TC-83 had E1 hotspots
at C10141T (Val, synonymous), C10371T (Ala-Gly), C10743G (Ala-
Gly), C11009A (Ala, minus sense, synonymous) and T11269C
(Asn, synonymous). Additionally, while there was no significant
difference in diversity when different cell types were used
(Fig. 3), TC-83 3x appeared to have an increased number of di-
versity hotspots in C7/10 cells than the other cell types.
2.7 Immunogenicity and protection against VEEV
challenge
Immunogenicity of the mutants was tested in an adult murine
model previously used to test the efficacy of TC-83 (Guerbois
et al. 2013). Adult CD-1 mice, 7 weeks of age, were vaccinated
with 5 log10 PFU in a 50 ll volume via the subcutaneous route.
Animals were bled on days 1–3 after vaccination and weighed
daily for 1 week and then again on days 11 and 14 (Fig. 5A).
Figure 1. A schematic of the TC-83 genome showing the placement of the four mutations in the RdRp gene (A). Growth curves of TC-83 and the RdRp mutants in inter-
feron negative Vero cells (B) or interferon competent HEK-293 cells (C). Experiments were performed in triplicate and titers were determined by standard plaque assay.
Repeated measures ANOVA was used to determine statistical significance, and bars indicate standard deviation. Resistance of TC-83 mutants to treatment by 5FU (D).
Cells were treated with 0, 10, 25, 50, 100, 200 or 300 mg/ml of 5FU and infected using an MOI of 0.01; all experiments were performed in triplicate. Samples were titered
by standard plaque assay. Statistical differences were determined by repeated measures ANOVA, and significance is detailed in the text. Resistance of TC-83 mutants
to treatment by Ribavirin (E). Cells were treated with 0, 50, 100, 200, 300 or 400 mM Ribavirin and infected using an MOI of 0.01; all experiments were performed in tripli-
cate. Samples were titered by standard plaque assay. Statistical differences were determined by repeated measures ANOVA, and significance is detailed in the text.
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Animals exhibited no weight loss and viremia was sporadic with
no significant differences among any of the viruses (repeated
measures ANOVA, Table 1). Four weeks post-vaccination, the ani-
mals were bled to assay neutralizing antibody titers (Fig. 5B). All
vaccinated mice exhibited a strong immune response as deter-
mined by a plaque reduction neutralization test (PRNT80). The 3x
and 4x mutants produced significantly higher mean neutralizing
antibody titers compared with TC-83 (repeated measures
ANOVA, p ¼ 0.0049 and 0.0012, respectively). Following challenge
at 6 weeks post-vaccination with VEEV subtype IC strain 3908,
which was used previously for similar experiments (Guerbois
et al. 2013; Rossi et al. 2013), animals were weighed daily and
monitored for survival (Fig. 5C and D). All vaccinated animals
showed complete protection from weight loss and death,
whereas the sham-vaccinated animals all succumbed by Day 9
post-challenge.
2.8 Hypermutator variation in attenuation
With the identification of the 3x and 4x viruses as potential fi-
delity mutants, it was important to determine if these viruses
were consistently less virulent in infant mice when subjected to
population bottlenecks. This was especially important to
confirm for the 3x mutant, because of its identification as a low-
fidelity mutant, which might make this strain less phenotypi-
cally stable. To test this, TC-83, TC-83 3x and TC-83 4x clones
were transcribed independently in duplicate. These constructs
were rescued using BHK cells, and each produced between
7 and 9 log10 PFU/ml following electroporation. To measure
virulence, 6-day-old CD-1 mice were injected intracranially or
subcutaneously with 105 PFU using these rescued viruses (Fig. 6).
Intracranial survival curves (Fig. 6A) were similar to those in
Fig. 2A, with most mice succumbing 5–7 days post-infection.
Backtiters of the inocula ranged from 4.8 to 8.8  104 PFU per
dose. Depending on the replicate group, TC-83 3x or TC-83 4x
were slightly more or less virulent than the parental TC-83. This
suggests that the RdRp mutations do not alter virulence when
administered intracranially, and that the significant differences
in lethality observed in Fig. 2A for TC-83 3x are likely dependent
on the mutant spectrum produced post-electroporation or due
to host variation.
Subcutaneous survival curves (Fig. 6B) were significantly differ-
ent compared with Fig. 2B. Instead of half of the 3x and 4x mutants
surviving subcutaneous inoculation, all individuals succumbed by
12 days post-infection. Inoculum back titers ranged from 3.5  104
to 1.1  105 PFU per dose. Although all mice succumbed, there was
variation between the replicates. For example, while one of the
TC-83 3x replicates survived an average of 7.9 days, the other repli-
cate survived an average of 9.6 days. This and the intracranial sur-
vival curve results suggest that differences in the post-
electroporation minority populations can result in variation in the
degree of attenuation of low-fidelity viruses.
2.9 Genetic stability in vitro and in vivo
To confirm that the fidelity-altering mutations did not revert
upon repeated replication, TC-83, TC-83 3x and TC-83 4x were
subjected to five passages in Vero cells. Sanger sequencing of
the RdRp revealed no mutations (data not shown).
Figure 2. Survival curves for the TC-83 mutants in 6-day-old CD-1 mice following intracranial injection (A) and subcutaneous injection (B) of 105 PFU. Statistical differ-
ences were determined using Kaplan-Meier tests, and significance is detailed in the text.
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The 3x and 4x RdRp mutants and TC-83 were also subjected
to 10 serial intracranial passages in infant mice to determine if
compensatory mutations accumulated in vivo. Passage 5 and 10
virus was injected subcutaneously into 6-day-old mice to assess
changes in virulence that occurred during passaging. TC-83, TC-
83 3x and TC-83 4x all gained virulence by passage 5 compared
with their unpassaged counterparts as shown in Fig. 2B
(Kaplan-Meier test, p  0.0001) (Fig. 7A). At this point, the 3x and
4x mutants reached virulence equivalent to that of the original,
unpassaged TC-83 with no significant difference in time to
death. Interestingly, no significant changes in virulence oc-
curred between passage 5 and 10 for any of the viruses. This in-
dicates that TC-83 3x and 4x can only reach virulence
equivalent to unpassaged TC-83, and are are unable to increase
in virulence past that point. Additionally, while not statistically
significant, mice inoculated with TC-83 4x passage 10 survived
up to 1 week longer than mice inoculated with TC-83 4x Passage
5. This suggests that additional passaging may result in de-
creased fitness for this construct.
2.10 Illumina sequencing for virus variants following
passaging
Illumina sequencing following mouse brain passage 5 showed an
increase in diversity for both TC-83 3x and TC-83 4x (Fig. 7B–F).
This suggests that TC-83 4x may actually be low fidelity, and that
multiple growth cycles may be required to truly assess fidelity
changes. Curiously, while diversity hotspots increased for both
TC-83 3x and 4x, the 6k hotspot observed after one cell culture
passage was greatly reduced for all of the passage 5 viruses
(Fig. 7D–F). Even though a different electroporation stock was
used for infant mice passaging, TC-83 3x and 4x still exhibited
fewer U-C mutations (Fig. 3C, Supplementary Fig. S5), suggesting
that this is a stable phenotype for these two RdRp mutants.
Although TC-83 3x and 4x were producing more diversity
than the parent TC-83, fewer revertents occurred at the E2 mu-
tation required for TC-83 attenuation (Fig. 7C) (Kinney et al.
1993). Due to the position of the 5’UTR attenuation mutation,
coverage was too low to assess true differences in the potential
for this site to also revert, but no reads contained the revertent
mutation for any virus. Following passage 10 in mouse brains,
Sanger sequencing was used to identify several SNPs (Table 2).
TC-83 and TC-83 3x each produced two SNPs following 10 pas-
sages, while TC-83 4x had no consensus sequence changes.
None of these SNPs reverted the TC-83 mutations that cause at-
tenuation or the inserted RdRp mutations. Additionally, there
were no convergent mutations found in all passage series.
3. Discussion
Infectious diseases transmitted by arthropod vectors are difficult
to control, and protecting the population via vaccination tends to
be more effective than trying to control or eradicate the vector
population. Although LAVs tend to be cost-effective and immu-
nogenic, LAVs have a significant Achilles’ heel: the potential for
reversion to wt virulence. This risk is particularly acute for RNA
viruses, which replicate without proofreading, resulting in an in-
creased ability to revert to the wt sequence or restore virulence
via compensatory mutations (pseudoreversion). However, alter-
ing virus fidelity can theoretically overcome this major draw-
back. This approach has only been examined with fidelity
mutants of PV and a low-fidelity ExoN mutant of SARS-CoV
(Graham et al. 2012; Vignuzzi et al. 2008). While the high fidelity
Figure 3. Illumina sequencing virus mutation frequency analysis of TC-83, 3x and 4x after 1 passage on Vero, HEK-293, C7/10 or U4.4 cells. Overall mutation frequency
for each cell type (A). Number of genomic positions with minority variants present above a frequency of 0.001 (B). Mutation frequency of different mutations (C). TC-83
3x: blue; TC-83 4x: green; TC-83: red. Repeated measures ANOVA was used to determine statistical significance, P < 0.05 is represented by *, P < 0.01 is represented by
**, P < 0.001 is represented by *** and P < 0.0001 is represented by ****.
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PV (Vignuzzi et al. 2008) and SARS-CoV ExoN (Graham et al. 2012)
mutant both demonstrated increased immunogenicity and an
improved safety profile compared to the parent viruses, this was
not observed for the low fidelity poliovirus (Korboukh et al. 2014).
However, fidelity mutants have only been generated using wt
virus strains, which are unlikely to be sufficiently attenuated for
vaccine use. We hypothesized that increasing the attenuation of
a live-attenuated RNA virus vaccine by altering the RdRp fidelity
would further improve its safety and efficacy. We addressed this
by validating a series of low-fidelity mutations in a model system
using the VEEV vaccine strain TC-83 to determine how this af-
fects the stability and attenuation. Serial passaging of TC-83 in
5-FU identified three mutations in the RdRp, and validation
showed that all three mutations were required to decrease virus
replication fidelity. Additionally, we identified a 4x mutant that
acted much like TC-83 3x, but showed no difference in diversity
after one cell culture passage.
At present, there is no atomic resolution structure for an
alphavirus RdRp, which limits our understanding of their mech-
anisms of fidelity alteration. However, all the mutations in the
3x mutant (G14R, E37G and A96T) were at the 5’ end of the nsP4
gene, similar to the placement of the PV high fidelity G64S and
low fidelity H273R substitution, which are both on the periphery
of the RdRp protein rather than near the active site (Pfeiffer and
Kirkegaard 2003; Campagnola et al. 2015; Korboukh et al. 2014).
For PV, the presence of the G64S mutation does not significantly
alter the structure of the polymerase, but it does decrease the
incorporation rate of new nucleotides (Arnold et al. 2005;
Marcotte et al. 2007). In fact, the current theory is that this sub-
stitution simply stabilizes the polymerase rather than altering
the active site. Alternatively, low fidelity H273R PV decreases
fidelity by favoring an open state of the RdRp, which decreases
the duration of this fidelity checkpoint, thus increasing the like-
lihood of NTP misincorporation (Moustafa et al. 2014). The pres-
ence of the low-fidelity mutations outside of the predicted active
domain of the TC-83 nsP4 gene suggests a similar mechanism,
but confirmation will require an atomic resolution structure.
There are two manners in which low-fidelity mutants have
been isolated, either by mutating residues found to alter fidelity
in other viruses or by passaging virus in the presence of a nucle-
oside analog. Of the latter (Arias et al. 2008; Pauly et al. 2017;
Van Slyke et al. 2015), three low-fidelity mutants have been
identified that are resistant to the nucleoside analog used for
passaging, but are sensitive to other nucleoside analogs. In con-
cordance with this, these low-fidelity mutants exhibit higher fi-
delity for the specific mutations selected by the nucleoside
analog, but lower fidelity for other mutations.
Our 3x and 4x fidelity mutants appear to act similarly to
these low-fidelity viruses, with resistance to 5’fluorouracil, but
not ribavirin. When examining the mutation frequency of dif-
ferent mutations, the fidelity mutants produced a much lower
amount of U to C transition mutations, which would be one of
the mutations expected to be selected against during 5’FU pas-
saging. This also may explain why the mutants are most resis-
tant to 5’FU when using moderate amounts of the nucleoside
analog, but then increase in susceptibility again at higher
Figure 4. Illumina sequencing virus diversity hotspots for the coding regions of TC-83, 3x and 4x genomes after 1 passage on Vero, HEK-293, C7/10 or U4.4 cells. A repre-
sentative replicate is pictured for each virus isolate from each cell type. For full results, see Supplementary Figs S1–S4. TC-83 (A, D, G, J), TC-83 3x (B, E, H, K) and TC-83
4x (C, F, I, L). Vero (A, B, C), HEK-293 (D, E, F), C7/10 (G, H, I) and U4.4 (J, K, L). Genome organization is color-coded using the following: nsP1, blue; nsP2, red; nsP3, green;
nsP4, purple; capsid, orange; E3, black; E2, gold; 6k, navy blue; and E1, maroon.
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concentrations, as there is no difference in the other uracil mu-
tation frequencies.
TC-83 3x was clearly a low-fidelity mutant, as evidenced by
the phenotypic tests, as well as the increased genetic diversity
observed using Illumina sequencing. The 4x mutant, while ex-
hibiting phenotypic similarities with other altered fidelity mu-
tants, had no significant difference in virus diversity compared
with the TC-83 parent after one cell culture passage. However,
TC-83 4x may actually be a low-fidelity variant, as suggested by
the increase in diversity that occurred during in vivo passaging,
which exhibited gains in diversity nearly identical to TC-83 3x.
Perhaps the C488Y mutation (Coffey et al. 2011), a high fidelity
CHIKV mutation, offers an additive effect to initially increase
virus diversity to that of wt virus, while exerting additional at-
tenuation via an unknown mechanism. However, it appears
that the C488Y mutation exerts less of an effect over multiple
virus replication cycles, resulting in increased virus diversity
compared with parent TC-83 after passaging in vivo.
Alternatively, it could be that the cumulative effect of these mu-
tations alters the ability of the virus to explore the most benefi-
cial sequence space as the virus replicates, leading to Muller’s
ratchet and decreased virus health. Indeed, this may explain
why the 4x mutant initially exhibited gains in virulence during
in vivo passaging, but later became more attenuated. It would be
interesting to continue passaging this mutant to determine if
the mutation threshold is eventually crossed, leading to error
catastrophe and virus extinction. If this hypothesis is validated,
the 4x construct is likely to be a safer LAV candidate than the 3x
mutant. Indeed, a mixture of these two hypotheses might ex-
plain the observed TC-83 4x results.
Also of interest is the C488Y substitution that increased rep-
lication fidelity in CHIKV, but did not affect TC-83 fidelity, al-
though it did attenuate TC-83 in the infant mouse model. This
finding is the opposite of the outcome for Sindbis virus, which
exhibited low-fidelity features when a low-fidelity CHIKV muta-
tion was inserted (Rozen-Gagnon et al. 2014). However, Sindbis
virus is more closely related to CHIKV than VEEV, so this may
explain why the effects did not transfer to TC-83 even though
the residue is highly conserved among alphaviruses (Coffey
et al. 2011).
Illumina sequencing uncovered many noteworthy effects
during RdRp mutant growth in vitro. In particular, the E1 diver-
sity peaks identified in TC-83 were greatly decreased for the
RdRp mutants. The E1 glycoprotein is responsible for the
uncoating of the virus particle and escape of the genome into
the cytosol. Some substitutions in the CHIKV E1 glycoprotein
Figure 5. Weight change, immunogenicity and survival following vaccination and challenge. Five-week-old mice were injected with 105 PFU of TC-83, 3x, 4x or mock in
a 50ul volume (n ¼ 8 per vaccine treatment). Mice were monitored daily for percent weight change from the original weight at D0 (A). The effectiveness of the vaccine
was determined by neutralizing antibody titer using serum from 6-week post-vaccination (B), and statistical differences were determined by repeated measures
ANOVA, where P < 0.01 is represented by **. Mice were challenged with 105 PFU of VEEV strain 3908 and were monitored for percent weight change from the original
weight at D0 (C) and survival (D).
Table 1. Viremia titers following vaccination with TC-83, TC-83 3x, TC-83 4x or mock.
Day 1 Day 2 Day 3
No. positive Average titer (6SD) No. positive Average titer (6SD) No. positive Average titer (6SD)
TC-83 3x 5/5 2.68 (60.52) 2/5 2.28 (60.21) 3/5 2.12 (60)
TC-83 4x 3/5 2.59 (60.49) 0/5 0 3/5 2.61 (60.59)
TC-83 4/5 2.94 (60.57) 1/5 2.73 (60) 2/5 2.47 (60.49)
PBS 0/5 0 0/5 0 0/5 0
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have been found to increase vector infectivity and transmission
(Tsetsarkin et al. 2007, 2011; Vazeille et al. 2007). Diversity in
this region may be important for increased vector fitness and/or
host jumps.
When total genome diversity was analyzed for each con-
struct, there was no significant difference in diversity when
comparing cell types. This is in contradiction to the low-fidelity
CHIKV mutants, which only showed increased diversity in ver-
tebrate cells and not in mosquito cells (Rozen-Gagnon et al.
2014). However, while no significant difference was observed in
overall diversity between the cell types, TC-83 3x produced
much higher peaks in diversity in C7/10 cells than was observed
in other cell types or viruses. This is intriguing, because it is hy-
pothesized that mosquitoes are drivers of diversity, likely due
to the sequence specificity of the mosquito antiviral RNAi re-
sponse (i.e. siRNAs), although this has only been demonstrated
for West Nile virus (Brackney et al. 2009, 2015; Grubaugh et al.
2015, 2017). This hypothesis does not appear to explain the in-
creased diversity observed during the TC-83 3x C7/10 passages,
because these cells lack a functional siRNA response.
Additionally, no increased hotspots were observed for U4.4
cells, which do produce antiviral siRNAs. Further work is
needed to determine how these diversity hotspots correspond
to small RNA targeting in mosquito cells and examine the ef-
fects of the host immune response on virus populations.
As previous studies have shown that high fidelity PV
mutations cause attenuation in mouse models by reducing dis-
semination to the central nervous system (Pfeiffer and
Kirkegaard 2005; Vignuzzi et al. 2006, 2008), we tested our mu-
tants in a lethal mouse model for TC-83. The 3x and 4x RdRp mu-
tants initially displayed equivalent virulence to parent TC-83
when injected into a single tissue that can cause lethal damage
(brain) and reduced virulence when injected via a multi-tissue
model (subcutaneous). However, when this experiment was re-
peated with virus rescued from different electroporation pools,
the 3x and 4x mutants displayed greatly increased virulence
compared with the initial subcutaneous outcome. This suggests
that minority variants randomly generated during the transcrip-
tion preceding electroporation can have large effects on the over-
all virus population health, and thus virulence. Importantly, TC-
83 was always equal to or more virulent when injected subcuta-
neously compared with the RdRp mutants. While TC-83 is not le-
thal in an adult mouse model, it would be interesting to
determine if the 3x and 4x mutants have consistently delayed
and/or decreased dissemination compared with wt virus. This
would allow for a greater understanding of how a low-fidelity
vaccine would operate in a fully immunocompetent host.
When it was established that different pools of virus may ex-
hibit different degrees of virulence, it became important to test
whether the mutants would remain attenuated when allowed
to experience multiple growth cycles. Perhaps counterintui-
tively, the 3x hyper mutator variant, while undergoing an initial
increase in virulence during in vivo passaging, only reverted to
the same level of virulence as unpassaged TC-83. This is likely
due to an increased amount of unfit virions (e.g. defective inter-
fering [DI] particles), which hamper wt virus virulence, as well
as the inability of the 3x mutant to revert the inserted RdRp mu-
tations. The passage 10 results for each virus were very similar
to the passage 5 data, except for the 4x virus, which decreased
in virulence so much that some infant mice were able to survive
7 extra days. This passaging data demonstrates that both of our
mutants exhibit decreased risk of reversion to wt virulence
compared with the parent TC-83.
As our study was designed to evaluate the effectiveness of
RdRp mutations that decrease fidelity in vaccines, the mutants
were put through a standard challenge model previously used for
different VEEV vaccines (Guerbois et al. 2013; Rossi et al. 2013).
Mice showed no adverse effects from vaccination, viremia was
consistent with that expected for TC-83, and all mice were pro-
tected against lethal challenge. Additionally, the mutants induced
higher antibody titers than TC-83. Our current hypothesis for this
observation is that the low-fidelity RdRp creates an increased
number of DI virus particles, which are well known to be strong
immune stimulators (Dimmock and Kennedy 1978; Mercado-
Lo´pez et al. 2013; Tapia et al. 2013; Sun et al. 2015). As VEEV first
amplifies in the draining lymph node (MacDonald and Johnston
2000), the presence of these DI particles may restrict dissemina-
tion from the draining lymph node, allowing for a greater oppor-
tunity for antigen presentation and therefore an increased
immune response. This needs to be explored in future work.
Here, we demonstrated that the presence of low-fidelity mu-
tations in a LAV resulted in reduced virulence in an infant
mouse model and increased immunogenicity in an adult mouse
model, both of which are desirable properties for LAVs.
However, we also observed different outcomes in low-fidelity
mutant attenuation in vivo when different pools of virus stock
were used, which suggests that the low-fidelity virus population
might not be initially stable. This demonstrates that there is
great need to understand the role that minority variants play in
phenotypic changes in vaccine development, as changes in the
mutant spectrum may significantly alter the phenotype of vac-
cines. However, the passaging results imply that the virus popu-
lation stabilizes after multiple growth cycles, so low-fidelity
RNA virus vaccines may require passaging to ensure a consis-
tent vaccination phenotype. Overall, this study demonstrates
that while low-fidelity mutations may be a potential tool to fur-
ther develop, the initial phenotypic instability observed post
Figure 6. Survival curves for the TC-83 mutants in 6-day old CD-1 mice following
intracranial injection (A) and subcutaneous injection (B) of 105 PFU from novel
RdRp mutant virus rescues. R1 denotes replicate 1. R2 denotes replicate 2.
Statistical differences were determined using Kaplan-Meier tests and are de-
tailed in the text.
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electroporation suggests that this may not currently be a viable
strategy for LAV development.
4. Materials and methods
4.1 Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Institutional Animal Care
and Use Committee of the University of Texas Medical
Branch.
4.2 Cell cultures and viruses
Vero (African green monkey kidney), HEK-293 and BHK cells
were obtained from the American type cell collection (Bethesda,
Figure 7. Survival of 6-day old CD-1 mice following subcutaneous injection with 105 PFU in a 50 ml volume of Passages 0, 5 or 10 TC-83, 3x or 4x from infant mouse intra-
cranial passages (A). Statistical differences were determined using Kaplan-Meier tests, and significance is detailed in the text. Illumina-sequencing diversity analysis
was used to determine changes in virus diversity of passage 5 TC-83, 3x or 4x in infant mice (B). Mutation frequency of the E2 8922 mutation required for TC-83 attenua-
tion (C). Illumina sequencing virus diversity hotspots for the coding regions of TC-83 (D), 3x (E) and 4x (F) genomes after five intracranial passages. Genome organiza-
tion is color-coded using the following: nsP1, blue; nsP2, red; nsP3, green; nsP4, purple; capsid, orange; E3, black; E2, gold; 6k, navy blue; and E1, maroon.
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MD) and maintained in Dulbecco’s minimal essential medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), and
Penicillin and Streptomycin (Pen/Strep) (100 U/ml) in a 37C, 5%
CO2 incubator. C7/10 cells were maintained in DMEM supple-
mented with 10% FBS, 1% minimal essential medium Non-es-
sential amino acids, 1% trypose phosphate broth and Pen/Strep
(100 U/ml) in a 30C CO2 incubator. U4.4 cells were maintained
in Mitsuhashi and Maramorosch media supplemented with 20%
FBS, 2% Sodium Bicarbonate (7.5%) and Pen/Strep (100 U/ml) in a
30C CO2 incubator. Viruses were rescued from a TC-83 infec-
tious clone as described previously and without further passage
(Smith et al. 2008). Viruses were passaged on Vero cells unless
otherwise stated. Titers of virus were determined by standard
plaque assay using Vero cells (Beaty et al. 1995).
4.3 Mutagenesis of TC-83
Parental TC-83 was passaged in the presence of mutagens,
Ribavirin (Sigma Aldrich, St Louis, MO), 5’Fluorouracil (5FU)
(Sigma Aldrich) or Azacytidine (Sigma Aldrich) at concentrations
of 40 mM, 80 mg/ml and 0.4 mM, respectively. Cells were pretreated
2 h prior to infection with the mutagens in duplicate, then in-
fected with TC-83 at a multiplicity of infection (MOI) of 1 PFU/cell.
Following a 1-h incubation period the cells were fed with DMEM
supplemented with 2% FBS and Pen/Strep (100 U/ml) as well as
the mutagen from the original pretreatment. Supernatants were
harvested 2 days post-infection and stored at 80C after being
supplemented with 10% FBS. Viral titers were determined by stan-
dard plaque assay (Beaty et al. 1995). Viruses were sequenced us-
ing Sanger sequencing after Passages 10, 18 and 23 to determine if
any mutations had occurred in the RdRp.
4.4 Manipulation of the TC-83 clone
Six TC-83 subclones containing mutations identified in the TC-
83 RdRp or high-fidelity CHIKV RdRp were created by joining-
PCR cDNA fragments from the TC-83 genome using designed
primers. The sequence of each construct was verified prior to
cloning into the genomic infectious clone backbone. All viruses
were rescued after electroporation into BHK cells as described
previously in Greene et al. (2005).
4.5 Testing of viral clones
To ensure that the inserted mutations did not interfere with vi-
ral replication, standard replication curves were conducted.
Cells were infected at an MOI of 1 (HEK-293) or 0.01 (Vero) in
12-well plates and incubated for 1 h before being washed twice
with phosphate buffered saline (PBS) and overlaid with 2 ml of
DMEM supplemented with 2% FBS and Pen/Strep (100 U/ml).
Virus was harvested by removing the entirety of the medium
and replacing it with 2 ml of fresh medium. Harvested virus was
supplemented with FBS to a final concentration of 20%, and
clarified by centrifugation at 3000 rpm for 5 min. The superna-
tant was then removed and stored at 80C. Viral titers were de-
termined by standard plaque assays (Beaty et al. 1995).
Rescued viruses were passaged five times on Vero cells to
ensure genetic stability. Viruses were harvested 2 days post-
infection and diluted 1:100 before infection of Vero cells in the
subsequent passage. Following Passage 5, viral suspensions
were placed into Buffer AVL (Qiagen, Valencia, CA) and RNA ex-
tracted using the column method as per the manufacturer’s
protocol. cDNA was produced using the Superscript III First
Round Synthesis kit (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. cDNA was amplified for sequenc-
ing using the Phusion enzyme (NEB, Madison, WI) in a 50 ll vol-
ume following the manufacturer’s instructions using primer
sets that covered the RdRp region of the genome (primers avail-
able upon request). Products were sequenced on the ABI 3700
sequencer (ABI, 3500).
Rescued viruses were tested for susceptibility to 5FU or
Ribavirin in triplicate. Cells were pretreated with 0, 10, 25, 50,
100, 200 or 300 mg/ml of 5FU or 0, 50, 100, 200, 300 or 400 mM
Ribavirin for 2 h. The cells were then infected with 0.01 MOI of
the RdRp mutants as well as TC-83. Medium containing the pre-
treatment amount of 5FU or Ribavirin was added to the infected
cells 1-h post-infection. Virus was harvested 24-h post-infection
and titrated in duplicate using standard plaque assays.
4.6 Virulence, immunogenicity and protection studies
To study virulence and attenuation, 6-day-old CD-1 mice
(Charles Rivers, Wilmington, MA) were inoculated intracranially
(IC) with 105 PFU of virus in a volume of 20 ll, or subcutaneously
(SC) with 105 PFU in a volume of 50 ll. Animals were weighed
daily for 2 weeks and monitored for survival.
In another experiment, 7-week-old CD-1 mice were vacci-
nated SC with the original TC-83 virus or one of the RdRp mu-
tants with 105 PFU in a volume of 50 ll, or with PBS for
unvaccinated controls (n ¼ 8 per cohort). Six-week post-
vaccination, animals were challenged SC with 105 PFU of wt
epidemic VEEV strain 3908 (Sua´rez et al. 2005), with daily moni-
toring for signs of illness, survival and weight loss. Blood sam-
ples were collected from alternating cages of vaccinated mice
for 3 days post-vaccination and 4 days post-challenge for vire-
mia detection, as well as 5 weeks post-vaccination for antibody
measurement by PRNT.
To assess genetic and phenotypic in vivo stability of the TC-
83 RdRp mutants, each was subjected to 10 serial, IC passages in
six-day-old CD1 mice at a dose of ca. 105 PFU in a 20 ll volume
per animal. Animals were euthanized 48-h post-inoculation,
and their brains harvested and homogenized to determine viral
titer by standard plaque assay (Beaty et al. 1995). The homoge-
nized brain was diluted to produce the same inoculum dose and
used to initiate the subsequent passage. Virulence of the mouse
passages 5 and 10 viruses was compared with the parental
strain by inoculating 6-day-old CD1 mice SC with 105 PFU, as de-
scribed earlier. Stability of the genomic sequences was assessed
by RT-PCR on RNA extracted from mouse passages 5 and 10 vi-
ruses and sequenced using Illumina or Sanger sequencing,
respectively.
4.7 Next generation sequencing
4.7.1 Library preparation
Viral RNA from cell culture extracts were fragmented by incuba-
tion at 94C for 8 min in 19.5 ll of fragmentation buffer
Table 2. Changes in nucleotide sequence following p10 in mouse
brain as verified by Sanger sequencing.
Amino acid
change
TC-83 3X TC-83 4X TC-83
nsP2 C3179T X
nsP4 T7208C X
E2 A8805T D-L X
3’UTR C11386T X
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(Illumina, San Diego, CA). First and second strand synthesis,
adapter ligation and amplification of the library were performed
using the Illumina TruSeq RNA Sample Preparation kit as per
the manufacturer’s protocol. For virus isolates from animals,
PCR was first done using sequence-specific primers tiled across
the VEEV genome to provide amplified products of 1.5 kb in
size that were used for library generation. Products were frag-
mented using transposons, then adapter ligation and amplifica-
tion of the library was performed using the Illumina TruSeq
RNA Sample Preparation kit under conditions described by the
manufacturer (Illumina, San Diego, CA). Samples were tracked
using the ‘index tags’ incorporated into the adapters as defined
by the manufacturer.
4.8 Sequence assembly and analysis
4.8.1 Quality and filtration
The quality for each sample/dataset was assessed using
FASTQC (Hoffmann et al. 2009). The paired-end reads were
merged for each sample and then filtered to exclude reads with
unknown characters (anything other than A, T, C, G) and low
quality (<10 quality score), so that only high quality reads were
used during analysis. Additionally, the first 16 bases of each
read were trimmed due to nucleotide bias.
4.8.2 Reference sequence
The analysis was performed using VEEV strain TC-83, complete ge-
nome (GenBank accession no.: L01443.1) (R. M. Kinney et al. 1989).
4.8.3 Virus diversity analysis
To analyze the variant hotspots, each sample was run through
a novel rare variant pipeline (available upon request). The pipe-
line first maps each read to the reference VEEV genome with
perfect match, then unmapped reads are re-mapped with 1 mis-
match and added to the final map. The 34 base long reads used
in the analyses were validated as viral sequences and not host
sequences by analysis of the longest subsequences shared ex-
plicitly (no mismatches allowed) and longest similar (1 mis-
match allowed) between viral and host genomes. Diversity per
position in the viral genome was calculated by taking a ratio of
the reads mapped with mismatches and all reads mapped at
that position. Positions in which the number of reads mapped
with mismatches was higher than perfectly mapped reads or
coverage was below 100 were excluded from diversity calcula-
tions. Mutation frequency per sample was calculated by sum-
ming per position diversities and normalizing by the number of
positions for which diversity was calculated. Positions with
non-zero mutation frequency were considered to be variant
positions.
4.9 Statistics
GraphPad Prism was used to perform all statistical tests, which
are described in the text.
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